Roche drug divarasib improves survival in lung cancer trial

divarasib Roche KRAS G12C mutation non-small cell lung cancer Krascendo-1 trial

Results from the Phase III Krascendo-1 clinical trial indicate that the investigational drug divarasib significantly improves survival rates for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).

In the randomized study, divarasib was compared against currently approved inhibitors sotorasib and adagrasib. Patients treated with divarasib achieved a median overall survival of 17.7 months, compared to 12 months for those receiving the existing therapies. The treatment also demonstrated a 44% reduction in the risk of death and a 42% reduction in the risk of disease progression or death.

Researchers from the MD Anderson Cancer Center noted that divarasib showed improved objective response rates and a more manageable safety profile, with fewer high-grade treatment-related adverse events and lower discontinuation rates. While the results suggest divarasib could become a new standard of care, the drug is still in clinical development and has not yet received regulatory approval.

Entities

Divarasib · European Society for Medical Oncology · Ferdinandos Skoulidis · MD Anderson Cancer Center · Merck · Pembrolizumab · Roche · Roche Holding AG · U.S. Food and Drug Administration

Claims

What the coverage asserts, and how many sources carry each claim.

[○ 1 SOURCE] Divarasib showed fewer high-grade treatment-related adverse events than sotorasib or adagrasib. www.hmpgloballearningnetwork.com
[● 7 SOURCES] The study targeted patients with KRAS G12C-mutated non-small cell lung cancer. schweiznews.ch · www.hmpgloballearningnetwork.com · ma-clinique.fr · diariodelweb.it · www.finanzen.ch · +2 more
[● 4 SOURCES] Divarasib reduced the risk of disease progression or death by 42%. ma-clinique.fr · www.finanzen.ch · www.news-medical.net · www.newswise.com
[○ 1 SOURCE] The objective response rate for divarasib was nearly twice that of sotorasib or adagrasib. www.finanzen.ch
[● 6 SOURCES] Divarasib achieved a median overall survival of 17.7 months in the Krascendo-1 trial. schweiznews.ch · ma-clinique.fr · diariodelweb.it · www.finanzen.ch · www.news-medical.net · +1 more
[● 7 SOURCES] The Krascendo-1 trial was a randomized Phase III study. schweiznews.ch · www.hmpgloballearningnetwork.com · ma-clinique.fr · diariodelweb.it · www.finanzen.ch · +2 more
[● 2 SOURCES] Divarasib is an investigational drug and is not yet approved. schweiznews.ch · diariodelweb.it
[● 6 SOURCES] Divarasib reduced the risk of death by 44% compared to sotorasib or adagrasib. schweiznews.ch · ma-clinique.fr · diariodelweb.it · www.finanzen.ch · www.news-medical.net · +1 more